Free Cash Flow

Forum Energy Technologies has extended its $250M credit facility to 2031, a move that strengthens its balance sheet and fuels its 'FET 2030' growth plans.

The insurance giant beat adjusted earnings estimates on strong operational performance, even as derivative losses weighed on its reported GAAP revenue.

DHI Group announces a $10M stock buyback, a bold move showing faith in its strategy as it navigates a complex, AI-driven tech recruitment landscape.

With its lead drug MOLBREEVI under FDA review, Savara's upcoming investor talks are a critical test of its path from clinical trials to market.

IUOE Local 150 backs Speaker Welch for State Central Committeeperson, signaling a major power play in Illinois Democratic politics post-Danny Davis.

The frozen potato giant appoints an AB InBev veteran as Executive Chair and a new CFO, signaling a major push for global expansion and shareholder value.

The AI boom runs on powerful chips that generate immense heat. Discover how the once-overlooked HVAC industry is now a critical infrastructure investment.

With a fresh capital infusion extending its runway into 2027, GRI Bio pushes ahead with promising clinical data for its IPF and autoimmune disease pipeline.

Amid financial scrutiny and following a major trial failure, Vistagen's upcoming Q3 update is a critical test for its novel pherine pipeline.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

A new study reveals financial firms see big returns from AI but struggle with deployment due to poor data quality and IT complexity, forcing a major rethink.

Digital asset firm Streamex appoints NYU's Anthony Marciano, signaling a strategic push for institutional credibility and M&A amid financial headwinds.

An expanded partnership aims to deliver a once-daily oral tablet for hypoparathyroidism, potentially revolutionizing treatment for thousands of patients.

Affinia Therapeutics gets the green light for a human trial of AFTX-201, a one-time therapy for a devastating genetic heart disease, BAG3 DCM.

Aethlon Medical's upcoming Q3 report puts its finances under a microscope as investors weigh a tight cash runway against progress on its Hemopurifier device.

Aramark has increased its quarterly dividend, a move reflecting strong financials. But what does it say about its strategy in a changing global market?

With key data on its Duchenne muscular dystrophy drugs expected in 2026, Entrada's CEO Dipal Doshi will detail the firm's high-risk, high-reward strategy.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

The firm's assets grew on market gains, but significant client outflows and shrinking fees triggered a sharp stock drop, revealing key industry pressures.

VENU closes a $13M deal for its first indoor venue, bringing an innovative fractional ownership "FireSuite" concept to the Denver area.